

From: [REDACTED]
Sent: samedi 4 mars 2017 16:40
To: [REDACTED]
Subject: Fw: Names of experts to be consulted during the study

Dear [REDACTED] fyi
Best
[REDACTED]
Sent from [Nine](#)

From: [REDACTED]
Sent: 2 Mar 2017 3:53 p.m.
To: [REDACTED]
Subject: Names of experts to be consulted during the study

Dear [REDACTED],

As you prepare your meetings with the successful bidder for the IP-related study, I take the liberty to suggest a few experts (most of them on IP issues) whom should be consulted during the study:

- 1) [REDACTED], LLM | Medicines Law & Policy, [REDACTED]
- 2) [REDACTED] Global Health Centre, Graduate Institute of International and Development Studies, Geneva- [REDACTED], Harvard TH Chan School of Public Health, [REDACTED]
- 3) [REDACTED] University of Barcelona, [REDACTED]
- 4) [REDACTED] University of Michigan, [REDACTED]
- 5) [REDACTED] Centre for Health Economics & Medicines Evaluation | Bangor University- [REDACTED]
- 6) [REDACTED], Knowledge Ecology International (KEI), [REDACTED]
- 7) [REDACTED], Drugs for Neglected Disease Initiative (DNDi) [REDACTED]
- 8) [REDACTED], MSF Access Campaign, [REDACTED]
- 9) [REDACTED], WHO, [REDACTED]

There are also quite a few names of experts in the U.S. who have done extensive research on the loopholes of the orphan drugs legislation. I am happy to add their names if necessary. I hope this is helpful for you. I remain at your disposal for any additional information/clarifications.

All the best,



[REDACTED]

European Public Health Alliance (EPHA) www.ephah.org



TOP 5 ISSUES IN MEDICINES POLICY FOR 2017

Editorial (NCE) and the Journal of the National Cancer Institute. The National Cancer Institute is not responsible for any use of the information contained in this journal.